Transition from IV to Subcutaneous Insulin After DKA Resolution
Administer subcutaneous basal insulin 2-4 hours before discontinuing the intravenous insulin infusion to prevent rebound hyperglycemia and recurrent ketoacidosis 1, 2.
Timing of Transition
The transition should be initiated when DKA has resolved, defined by:
- Blood glucose <200 mg/dL
- Serum bicarbonate ≥18 mEq/L
- Venous pH ≥7.3
- Anion gap closure (≤12 mEq/L)
Critical timing requirement: The subcutaneous basal insulin must be given 2-4 hours before stopping IV insulin 1, 2. This overlap period is essential—abrupt discontinuation of IV insulin without adequate subcutaneous coverage leads to recurrence of ketoacidosis and poor glycemic control 3.
Recommended Dosing Regimen
Basal-Bolus Approach (Preferred)
Calculate total daily dose (TDD):
- Take 50% of the total 24-hour IV insulin requirement when glucose was stable
- Alternatively, use 0.5-1 unit/kg body weight 4
Distribute the TDD:
- 50% as basal insulin (long-acting: glargine or detemir) given once daily in the evening
- 50% as prandial insulin (rapid-acting analog) divided equally before three meals 4
For example, if a patient required 48 units of IV insulin over 24 hours:
- Basal insulin: 24 units once daily (evening)
- Prandial insulin: 8 units before each meal
Adjustment for Oral Intake
If the patient has poor or uncertain oral intake, reduce the prandial insulin dose by 50% or use basal insulin with correction doses only 4.
Emerging Evidence: Early Basal Insulin Strategy
Recent high-quality evidence supports administering low-dose basal insulin (0.15-0.3 units/kg) during the IV insulin infusion phase 1. This approach:
- Reduces time to DKA resolution by approximately 4 hours 5
- Prevents rebound hyperglycemia after IV insulin discontinuation
- Does not increase hypoglycemia risk 5, 6
- May shorten hospital length of stay 1
This strategy is particularly valuable as it eliminates the risk of forgetting to administer basal insulin before stopping the IV infusion—a common pitfall that leads to metabolic decompensation.
Critical Pitfalls to Avoid
Never stop IV insulin without prior subcutaneous basal insulin administration—this is the most common error leading to DKA recurrence 3, 7
Avoid "sliding scale" or correction-only insulin regimens without basal coverage in the post-DKA period 1
Do not rely solely on anion gap normalization for transition timing—ensure all resolution criteria are met, including bicarbonate ≥18 mEq/L and pH ≥7.3 3
Continue long-acting insulin analogs (glargine/detemir) at usual doses if the patient was already taking them before DKA 8
Monitoring After Transition
- Check blood glucose every 2-4 hours initially 1
- Monitor for rebound hyperglycemia (>250 mg/dL) or recurrent ketosis
- Assess for hypoglycemia (<70 mg/dL) and adjust regimen accordingly 1
- If ketosis recurs (blood ketones >1.5 mmol/L or ketonuria 2+), restart IV insulin immediately 4
Type 1 vs Type 2 Diabetes Considerations
Type 1 diabetes: Basal-bolus regimen is mandatory—these patients have absolute insulin deficiency and cannot be managed without both components 4.
Type 2 diabetes: May use simplified regimens if:
- Mild hyperglycemia (<200 mg/dL) at presentation
- Low home insulin requirements (<0.6 units/kg/day)
- HbA1c <8.5%
In these cases, basal insulin alone with correction doses may suffice initially 9.
The evidence strongly supports a structured transition protocol with mandatory basal insulin administration 2-4 hours before IV insulin cessation, using a basal-bolus regimen calculated from prior IV insulin requirements. The newer strategy of early basal insulin initiation during the IV phase represents an evidence-based advancement that improves outcomes without compromising safety 1, 5.